| Course | DDBA 8541 Seminar in Entrepreneurial Finance |
|---|---|
| Week | Week 5 |
| Paper type | Milestone memo |
| Length | About 580 words, 4 pages |
| Format | Memo, APA 7 citations |
| School | Walden University |
| Program | Doctor of Business Administration (DBA) |
| Updated | October 2026 |
Free sample paper for DDBA 8541 Week 5
Memorandum
To: Investment committee, seed syndicate
From: Lead investor's analyst
Date: February 9, 2026
Re: Milestones governing release of the second tranche to the assay venture
Recommendation
I recommend that the second tranche of $3.5 million be released when, and only when, three milestones are met by the dates below: independent analytical validation of the assay, a premarket notification filed with the Food and Drug Administration and a purchase order from a hospital laboratory at or above a stated price. Each is written so that two people reading the same documents would reach the same verdict.
The Venture
SepTrace, a composite company in Minneapolis, is developing a blood test that detects markers of sepsis within ninety minutes, intended for hospital laboratories. Our syndicate has committed $5 million in two tranches: $1.5 million at closing and $3.5 million on the milestones. Sahlman (1990) described staged financing as a way for investors to keep the option to stop funding when new information arrives, and Gompers (1995) showed that rounds come smaller and closer together where an investor finds the company hard to watch. A diagnostic venture before validation fits that description.
The Milestones
[after]
Table 1
Second Tranche Milestones
| Milestone | Measure and threshold | Who measures | Proof | Deadline | |
|---|---|---|---|---|
| Analytical validation | Sensitivity of at least 90 percent and specificity of at least 85 percent on at least 300 banked clinical samples | Independent clinical laboratory under contract with the syndicate | Laboratory's signed validation report | December 31, 2026 | |
| Regulatory submission | Premarket notification submitted to the FDA | FDA | Agency's acknowledgment letter with submission number | March 31, 2027 | |
| Commercial demand | Purchase order from a hospital laboratory for at least 2,000 tests at no less than $55 each | Purchasing hospital | Signed purchase order on hospital letterhead | March 31, 2027 | |
Why Each Is Written This Way
Validation is measured by an independent laboratory rather than SepTrace's own staff, so SepTrace cannot shade the reading of its own data. The thresholds and the sample count are stated, so "promising results" cannot substitute.
The regulatory milestone is submission, not clearance. Clearance timing is outside SepTrace's control and could take many months after a complete submission, so tying money to clearance would punish the company for the agency's schedule. Submission, proved by the acknowledgment letter, is within its control and shows that the validation data and documents are complete enough to file. We make no assumption that clearance will follow.
The commercial milestone sets a price floor and a minimum quantity, so a token order at a deep discount from a friendly customer cannot satisfy it. Kaplan and Stromberg (2003) found that venture contracts frequently make investors' rights and commitments depend on measurable performance, and this milestone follows that practice for demand.
If a Deadline Passes
If any milestone is unmet by its date, the tranche does not release automatically. The syndicate then decides, by majority, whether to extend the deadline, fund on new terms or decline further funding. SepTrace keeps the first tranche and its existing rights in all cases.
Reporting Between Tranches
SepTrace will send the syndicate a one-page report each quarter showing progress toward each milestone, so a missed deadline is never a surprise.
Risks
SepTrace could meet the milestones and still fail commercially; milestones reduce uncertainty, they do not remove it. Staging also gives the company reason to focus on what is measured, which is why each milestone ties to something we actually need to know.
References
Gompers, P. A. (1995). Optimal investment, monitoring, and the staging of venture capital. Journal of Finance, 50(5), 1461-1489. https://doi.org/10.1111/j.1540-6261.1995.tb05185.x
Kaplan, S. N., & Stromberg, P. (2003). Financial contracting theory meets the real world: An empirical analysis of venture capital contracts. Review of Economic Studies, 70(2), 281-315. https://doi.org/10.1111/1467-937X.00245
Sahlman, W. A. (1990). The structure and governance of venture-capital organizations. Journal of Financial Economics, 27(2), 473-521. https://doi.org/10.1016/0304-405X(90)90065-8
What the DDBA 8541 Week 5 instructions ask for
Week 5 asks you to write the milestones that govern a staged investment. Lead with your recommendation. Describe the venture and the tranche structure briefly. Set out each milestone in a table with the measure and threshold, who measures it, the document that proves it and the deadline. Explain each design choice by showing how a looser version could be met on paper while its purpose is missed. State what happens if a deadline passes. Use research on staged financing to explain why the milestones exist, and note the risks that remain even if every milestone is met.
How this DDBA 8541 Week 5 example is built
The sample memo recommends releasing the tranche only when all three milestones are met. Validation is measured by an independent laboratory under contract with the syndicate, not by company staff. The regulatory milestone is submission rather than clearance, because clearance timing lies with the agency, and the memo makes no assumption that clearance will follow. The commercial milestone sets both a quantity and a price floor so a discounted order from a friendly customer cannot satisfy it. If a deadline passes, the syndicate votes on extending, refunding on new terms or stopping. A quarterly one-page progress report is added. Risks note that a venture can meet every milestone and still fail commercially, and that staging rewards whatever is measured.
Where the marks sit in the DDBA 8541 Week 5 rubric
Checkability drives the grade: for each milestone, graders ask whether two readers holding the stated documents would reach the same verdict, and terms such as substantial progress fail at once. Resistance to gaming comes next, through independent measurement, submission rather than approval and price floors. A memo whose milestones can be met while their purpose is missed loses heavily. Sequence and deadlines earn credit when they match how the venture would actually progress. Sources earn marks when used for what staging is for. Clear consequences for missed deadlines show the memo would work in practice. Plain language that a founder and an investor would read the same way is itself part of checkability.
DDBA 8541 Week 5 help: mistakes that cost marks
For each milestone, imagine a founder under pressure trying to meet it the easy way, then close that route. Name the person or institution that measures, and choose one outside the company where possible. Name the exact document that proves the result. Avoid milestones whose timing depends on a regulator or a court. Set dates that allow for normal delays. Keep the memo short; the table carries the substance. Explain what the syndicate decides if a milestone is missed, so no one assumes automatic consequences. A short section on reporting between tranches helps both sides track progress. Finally, note the risks milestones cannot remove, such as commercial failure after every condition is met, so the committee does not overestimate what staging buys.
Get a DDBA 8541 Week 5 example written to your instructions
Tell the desk what the tranche is meant to fund and attach the Week 5 prompt and rubric; the memo and its milestone table return within 24 to 48 hours, free the first time. If your case gives technical thresholds, such as a validation target, include them, since invented ones are marked as illustrative in the sample.
More DDBA 8541 papers and DBA samples
- DDBA 8541 Week 1: SAFE Rights Discussion
- DDBA 8541 Week 2: Demand Evidence Note
- DDBA 8541 Week 3: Venture Assumptions Brief
- DDBA 8541 Week 4: Preferred Stock Analysis
- DDBA 8541 Week 6: Information Asymmetry Paper
- DDBA 8541 Week 7: Venture Model Peer Critique
- DDBA 8541 Week 8: Founder Control Analysis
- DDBA 8541 Week 9: Sample Frame Appraisal
- DDBA 8541 Week 10: Exit Waterfall Analysis
- DDBA 8541 Week 11: Financing Seminar Paper
- DDBA 8531 Week 5: Switching Cost Brief
- DDBA 8524 Week 5: Language Policy Memo
- DDBA 8522 Week 5: End-of-Life Supply Chain Trace
- DDBA 8521 Week 5: Change History Brief
DDBA 8541 Week 5 questions, answered
Where can I find a free DDBA 8541 Week 5 sample paper?
SepTrace's second-tranche memo, milestone grid included, is reproduced under the sample heading, unpaid.
What tranche does the DDBA 8541 Week 5 memo govern?
A second tranche of $3.5 million in a $5 million seed commitment to a sepsis assay venture.
Why is FDA submission the milestone rather than clearance?
Clearance timing is outside the company's control, while a complete submission is within it.
Who measures analytical validation?
An independent clinical laboratory under contract with the syndicate.
What happens if a deadline passes?
The tranche does not release, and the syndicate decides by majority whether to extend, refund on new terms or stop.